About the NCCN Compendium®

Based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Compendium contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.

The recommendations for appropriate use of drugs and biologics contained in the NCCN Compendium are extracted directly from the relevant NCCN Guidelines® along with their clinical context, route of administration, recommended use, and NCCN Category of Evidence. NCCN staff pharmacists generate the NCCN Compendium at the agent level rather than regimen; however, these agents reflect the components of regimens used in disease management. In addition to Guidelines-specific indication and use, NCCN adds relevant information such as pharmacologic class, relevant ICD-10 codes, and U.S. Food and Drug Administration (FDA) indication to the searchable database. Compendium development and maintenance is accomplished by disease site and reviewed by members of the relevant NCCN Guidelines Panel before publication.

The NCCN Compendium is recognized by public and private insurers alike, including, but not limited to the Centers for Medicare and Medicaid Services (CMS) and UnitedHealthcare, as an authoritative reference for oncology coverage policy. Managed care medical directors, pharmacy benefits directors, and other health care professionals also reference the NCCN Compendium when making decisions that impact patient access to appropriate therapy. The uses identified are based upon evaluation of evidence from scientific literature integrated with expert judgment in an evidence-based process. Indicated uses are categorized in a systematic approach that describes the type of evidence available for and the degree of consensus underlying each recommendation. All recommendations (at all category levels) in the NCCN Compendium constitute appropriate, medically necessary care. The NCCN Compendium lists both FDA-approved uses and appropriate uses beyond the FDA-approved label.

The NCCN Compendium is accessible through an easy-to-use web-based user interface and includes a full complement of drugs and biologics recommendations found in the currently published Guidelines. The NCCN Compendium is reviewed on a continual basis to ensure that the recommendations take into account the most current evidence.
The top menu of the NCCN Compendium contains various drop-down lists for displaying the database.

An easy-to-read view of the selected compendium entries can be made available for printing or saving as a PDF by checking the box in the left most column.
To display the content of your choice, select any item from the drop-down menus. You can start with any of the menus and choose from the available options in one or multiple lists.

If you continue to filter the database using additional drop-down menus, they will automatically adjust to narrow down the available options based on each of your previous selections.
The data table will display default data fields, including: Guideline, Disease, Agent, Brand, Pharmacologic Class, Histology, Route(s), ICD-10 Codes, NCCN Recommended Use, NCCN Category of Evidence, Chemotherapy Order Template(s), and FDA approved indication(s).

3. The Guideline hyperlink will lead to the front page of the NCCN Guidelines where users can navigate to the appropriate page.

3. The Brand name hyperlink will lead to the most recent prescribing information (also known as the label or package insert) posted on the FDA website.

3. The Panel Disclosure hyperlink will lead to the list of current panel members and their most recent disclosure(s) for the associated NCCN Guidelines.

3. Hovering over the chemotherapy order template acronym will display the full name of the regimen. Click on the hyperlink to view the chemotherapy order template associated with the compendium entry.

3. Hovering over the NCCN Category will display more information about what each category represents. Compendium entries may contain multiple recommendations that each correspond to different categories of evidence.

3. Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
The NCCN Compendium is built on a responsive platform that can be viewed on mobile devices. If the screen size cannot accommodate all data fields simultaneously, the interface will automatically hide certain fields and indicate this with a red numbered icon in the left most column of the data table.

A red numbered icon indicates hidden fields when viewed on mobile devices, tablets, or reduced screen sizes. Click on the icon to view additional fields in a vertical display.
With the desired content displayed, individual or multiple records may be selected for printing by checking the printer icon box (left-most data field).

Print the page or save the record as a PDF.

### NCCN Drugs and Biologics Compendium®

**Disease Information**

- **Guideline Name:** Breast Cancer 1.2018
- **Disease:** Ductal Carcinoma in situ
- **Agent:** Anastrozole
- **FDA Indication:** Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. Anastrozole is indicated for first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. Anastrozole is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole.
- **Brand:** Arimidex®
- **Category of Evidence:** 1 following breast-conserving therapy and radiation 2A for all others
- **Histology:** Ductal carcinoma in situ (DCIS)
- **Pharmacologic Class:** Selective nonsteroidal aromatase inhibitor
- **Route:** PO
- **Recommended:** Risk-reduction endocrine therapy for ipsilateral breast for 5 years for postmenopausal patients with hormone receptor-positive DCIS following surgery
- **ICD-10:** D06.10-D05.12, D05.80-D05.82, D05.90-D05.92, Z79.819, Z91.89

The NCCN Drugs and Biologics Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most-up-to-date version, please visit NCCN.org. The NCCN Drugs and Biologics Compendium® and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
Information regarding No Longer Recommended Uses and the Transparency documents for each update of the NCCN Guidelines® and associated Compendium chapter(s) is available by clicking on the options at the top of the Compendium display.

“No Longer Recommended Uses” is a list of archived compendium entries that describe drugs and biologics previously (but no longer) recommended in the associated NCCN Guidelines.

The Transparency: Process and Recommendations page lists the NCCN Guidelines updates by version and year, panel meeting date(s), attendance, evidence reviewed during the meeting, and the outcome of any discussions and voting that took place. A link to the panel disclosures at the time of the update is also available for each transparency posting.